市場調查報告書

自我給藥型的自體免疫注射劑

Self-Administered Autoimmune Injectables

出版商 Greystone Research Associates 商品編碼 745211
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
自我給藥型的自體免疫注射劑 Self-Administered Autoimmune Injectables
出版日期: 2019年10月31日內容資訊: 英文
簡介

本報告以自我給藥型的自體免疫注射劑市場為焦點,提供全面的評估,及技術、產品、市場參與企業的分析。

摘要整理

市場動態

  • 競爭情形
  • 醫藥品供應鏈活動
  • 產品設計、啟用要素
  • 可用性
  • 患者醫囑遵從性
  • 投藥頻率
  • 人因工程/人體工學
  • 售前、售後設備的發展

自我給藥型注射劑

  • 設備的選擇:穩定性、材料的課題
  • 預填充式注射器
  • 自動注射器
  • 特殊功能自動注射器
  • 筆型注射器
  • 雙心腔型筆
  • 新的設備

自我給藥型自體免疫治療藥:產品簡介

  • mAb (單株抗體)
  • 細胞激素
  • 融合蛋白質

自體免疫療法市場評估

  • 僵直性脊椎炎
  • 克隆氏症
  • 成人類風濕性關節炎
  • 幼年特發性關節炎
  • 多發性硬化症
  • 乾癬性關節炎
  • 潰瘍性大腸炎

市場要素

  • 法規要素
  • 臨床實驗通訊協定 & 端點
  • 聯盟、聯盟

企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: SJA616F

The advantages of administering immunotherapeutic injectables subcutaneously is now well accepted and has been more-or-less institutionalized in the drug life cycle development process for non-oncology indications. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. The migration to patient self-care presents several areas of concern. By making the patient the single point of failure for dosing adherence and successful drug delivery, devices and protocols must be developed and tested to a new, higher standard. New generation drug injection devices are increasingly being created to address patient adherence issues by making the delivery of injectable drugs less complicated and intimidating

Self-Administered Autoimmune Injectables - What You Will Learn

  • What approved drugs indicated for autoimmune conditions are marketed for self-administration, what is the as-supplied packaging, and who markets them?
  • What are the major factors driving the migration of infusible drugs for treating autoimmunity to formulations that can be packaged and administered subcutaneously?
  • What is the size of the market for self-administered autoimmune injectable drugs today, who are the market share leaders, and what will the market share be in 2022?
  • How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
  • What are the essential design factors, technologies and market development issues for devices that can deliver injectable autoimmune drugs subcutaneously?
  • What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?

Table of Contents

Self-Administered Autoimmune Injectables - Summary of Contents

Executive Summary

Market Dynamics

Competitive Landscape

  • Drug Supply Chain Activity
  • Product Design and Enablement Factors
  • Ease of Use
  • Patient Adherence
  • Dosing Frequency
  • Human Engineering/Ergonomics
  • Pre- and Post-Marketing Device Evolution

Self-administered Enabling Devices

Device Selection - Stability and Material Issues

  • Prefilled Syringes
  • Autoinjectors
  • Special Feature Autoinjectors
  • Pen Injectors
  • Dual Chamber Pens
  • Emerging Devices

Self-administered Therapeutic Autoimmune Drugs

mAbs

  • Cytokines
  • Fusion Proteins

Autoimmune Therapeutics Markets

Ankylosing Spondylitis

  • Crohn's Disease
  • Adult Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Psoriatic Arthritis
  • Ulcerative Colitis

Market Factors

Regulatory Factors

  • Clinical Trial Protocols & Endpoints
  • Alliances and Partnerships

Company Profile

Back to Top